This trial is evaluating whether Regularized Sleep Schedule will improve 20 primary outcomes in patients with Sleep. Measurement will happen over the course of 2 weeks.
This trial requires 112 total participants across 3 different treatment groups
This trial involves 3 different treatments. Regularized Sleep Schedule is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
We found that risk factors for CVD are not only present in, but predictive of, CVD. A number of factors related to both risk and prevention should be considered with these patients, such as lifestyle modification, optimal diet and control of blood pressure.
There are numerous factors that could contribute to higher CVD risk, but there seems to be little or no difference in CV risk between men and women. Diabetes and CVD risk factors, such as high blood pressure, high blood cholesterol and BMI, are positively associated with higher CVD risk in women.
The most frequent diagnoses and treatments for the cardiovascular risk condition were hypertension treatment, aspirin use, anti-smoker counseling, screening for dyslipidaemia, blood pressure counseling, and regular physical activity.
This is the first study to provide national estimates of cardiovascular risk in all adults in the U.S., measured via FRS, CVD, and diabetes risk scores, and has found significant variation by racial and ethnic group. This has an important implication for both clinical practice and public policy.
Atherosclerosis may be managed (i) by the use of preventive treatments for the patient to halt the onset of cardiovascular events; (ii) by the use of vascular interventions to prevent future cardiovascular events; and (iii) by the use of pharmacologic medications to keep arterial blood pressure, blood lipids, or blood glucose in desired ranges.
Clinicians must not underestimate their responsibility when making clinical decisions for patients presenting with a CVD risk profile. Even when patients are eligible for clinical trials, there appears to be a need for more information to assess the relevance of any individual risk factor in both the population as a whole and in individual patients before participation in a clinical trial. The clinical relevance of some common cardiovascular risk factors should be evaluated in prospective study population samples of patients with or without CVD. This is particularly relevant at this time when the relative risks of CVD are debated between statins and blood pressure reduction.
The present study demonstrated, for the first time, a significant association between a night sleep schedule and HRQOL among those with cardiovascular risks. However, there is no significant interaction between sleep wake schedule and HRQOL, so sleep schedule-based intervention could be helpful for those who have a difficulty in sleep at work and a busy lifestyle in a healthy lifestyle.
The national median overall age at cardiovascular risk was 73 years. However, this varies according to ethnicity. White men and women had significantly lower ages at cardiovascular risk when compared to other racial/ethnic groups. Moreover, when stratified by age, there were racial/ethnic differences when using the FRS calculator, and more stringent definitions of cardiovascular risk are needed for ethnic minorities.
Although common risk factors for coronary heart disease and heart attack are well documented, many people, including those considered to be in good health, may not be advised to undergo screening for these common risk factors. The magnitude and consequences of cardiovascular risk need further discussion.
As cardiovascular risk is a common end-point in clinical research, physicians who see large number of patients are most likely to be most knowledgeable of cardiovascular risk. Data from a recent study reveal that cardiovascular risk is most commonly caused by hypertension or hyperlipidemia (66% and 24%) and is also most common after the age of 40 (61%), with a slight gender difference. These data suggest that most cardiac and vascular risk in clinical research populations comes from two well-recognized sources as a primary endpoint.
The study demonstrates, for the first time, that a regularized sleep schedule is not a dominant factor in the use of adjunctive therapies. These data suggest that more studies are warranted to investigate whether adherence to an individualized exercise program in addition to a regular sleep schedule promotes positive clinical outcomes in individuals with chronic obstructive pulmonary disease.